{"id":175642,"name":"THE CAMPAIGN FOR SUSTAINABLE RX PRICING","slug":"the-campaign-for-sustainable-rx-pricing","state":"DC","description":"A coalition of organizations working on market-based solutions to drug pricing.","totalSpending":2250000,"filings":27,"yearlySpending":[{"year":2018,"income":320000},{"year":2019,"income":320000},{"year":2020,"income":520000},{"year":2021,"income":330000},{"year":2022,"income":220000},{"year":2024,"income":180000},{"year":2025,"income":360000}],"firms":["MEHLMAN CONSULTING, INC."],"lobbyists":["BRUCE MEHLMAN","DAVID CASTAGNETTI","DEAN ROSEN","CONSTANTINE HINGSON","DAVID THOMAS","ELISE FINLEY PICKERING","SOHINI GUPTA","SAGE EASTMAN","LAUREN ARONSON","MICHAEL ROBINSON","MICHAEL COLLINS","STEVE HARO","HELEN TOLAR","NICHOLE DISTEFANO","MCKENZIE BRICE","PAUL THORNELL","STEPHEN COTE","ALEXANDER PERKINS","VICTORIA FLOOD","ROSEMARY GUTIERREZ","ZACHARY MALLOVE","CAITLIN VAN SANT","LISA GOLDMAN","ALYENE MLINAR","ERICA CHABOT","ANNIE WOLF","NAVEEN PARMAR","JON ADAME","JOSEPH BROWN","EARL FLOOD"],"issues":["HCR","MMM","PHA","BUD","CPT","TRD"],"sampleDescriptions":["Prescription drug pricing.\nS. 974 - CREATES Act.\nS. 1131 and H.R. 2439 - Fair Accountability and Innovative Research Drug Pricing Act\nH.R. 2051 - FAST Generics Act of 2017.\nMedicare Part D Biosimilars.\nH.R 1892 - The Bipartisan Budget Act of 2018, Omnibus","Prescription drug pricing.\nMedicare Part D Biosimilars.\nH.R. 1892 - The Bipartisan Budget Act of 2018, Omnibus","Prescription drug pricing.\nS. 974 - CREATES Act.\nS. 1131 and H.R. 2439 - Fair Accountability and Innovative Research Drug Pricing Act\nH.R. 2051 - FAST Generics Act of 2017\nMedicare Part D Biosimilars.","H.R. 1892 - The Bipartisan Budget Act of 2018, Omnibus","Prescription drug pricing.\nS. 974 - CREATES Act.\nS. 1131 and H.R. 2439 - Fair Accountability and Innovative Research Drug Pricing Act\nH.R. 2051 - FAST Generics Act of 2017.\nMedicare Part D Biosimilars.","Prescription drug pricing.\nMedicare Part D Biosimilars.","Prescription drug pricing.\nS. 974 - CREATES Act.\nS. 1131 and H.R. 2439 - Fair Accountability and Innovative Research Drug Pricing Act\nH.R. 2051 - FAST Generics Act of 2017.\nMedicare Part D Biosimilars.\nH.R.6 - SUPPORT for Patients and Communities Act.\nS. 3120 - HEAL Act of 2018.\nS. 2553: Know the Lowest Price Act of 2018.\nS. 2554: Patient Right to Know Drug Prices Act.","Prescription drug pricing.\nMedicare Part D Biosimilars.\nH.R.6 - SUPPORT for Patients and Communities Act.\nS. 2553: Know the Lowest Price Act of 2018.\nS. 2554: Patient Right to Know Drug Prices Act.","Prescription drug pricing.\nS. 974 - CREATES Act.\nS. 1131 and H.R. 2439 - Fair Accountability and Innovative Research Drug Pricing Act\nH.R. 2051 - FAST Generics Act of 2017\nMedicare Part D Biosimilars.\nH.R.6 - SUPPORT for Patients and Communities Act.\nS. 2553: Know the Lowest Price Act of 2018.\nS. 2554: Patient Right to Know Drug Prices Act.","Prescription drug pricing.\nS. 340 - CREATES Act of 2019.\nH.R. 985 - FAST Generics Act of 2019.\nH.R. 1520 - Purple Book Continuity Act of 2019.\nH.R. 1503 - Orange Book Transparency Act of 2019.","Prescription drug pricing.","Prescription drug pricing.\nHHS Rebate Rule.","Patent abuse.\nS. 440 - PACED Act\nH.R. 2375 - Preserve Access to Affordable Generics and Biosimilars Act\nH.R. 1499 - Protecting Consumer Access to Generic Drugs Act of 2019\nS. 617 - Second Look at Drug Patents Act of 2019\nS. 1416 - The Affordable Prescriptions for Patients Act\nS. 1224 - The Stop STALLING Act","Prescription drug pricing.\nS. 1895 - Lower Health Care Costs Act\nS. 1416 - Affordable Prescriptions for Patients Act\nS. 1224 and H.R. 2374 - Stop Significant and Time-Wasting Abuse Limiting Legitimate Innovation of New Generics (STALLING) Act\nS. 440 - Preserving Access to Cost Effective Drugs Act\nS. 340 and H.R. 965 - CREATES Act\nS. 1391 & H.R. 2296 - Fair Accountability and Innovative Research Drug Pricing Act\nH.R. 1520 - Purple Book Continuity Act\nH.R. 1503 - Orange Book Continuity Act\nS. 659 - Biologic Patent Transparency Act\nS. 551 - Recovering Excessive Funds for Unused and Needless Drugs (REFUND) Act\nS. 1209 - Reforming Evergreening and Manipulation that Extends Drug Years (REMEDY) Act\nH.R. 2113 - Prescription Drug STAR Act\nS. 617 - Second Look at Drug Patents Act of 2019","Prescription drug pricing.\nS. 1895 - Lower Health Care Costs Act\nS. 1416 - Affordable Prescriptions for Patients Act\nS. 1224 and H.R. 2374 - Stop Significant and Time-Wasting Abuse Limiting Legitimate Innovation of New Generics (STALLING) Act\nS. 440 - Preserving Access to Cost Effective Drugs Act\nS. 340 and H.R. 965 - CREATES Act\nS. 1391 & S. 2296 - Fair Accountability and Innovative Research Drug Pricing Act\nH.R. 1520 - Purple Book Continuity Act\nH.R. 1503 - Orange Book Continuity Act\nS. 659 - Biologic Patent Transparency Act\nS. 551 - Recovering Excessive Funds for Unused and Needless Drugs (REFUND) Act\nS. 1209 - Reforming Evergreening and Manipulation that Extends Drug Years (REMEDY) Act\nH.R. 2113 - Prescription Drug STAR Act\nH.R. 985 - FAST Generics Act of 2019.","Prescription drug pricing.\nHHS Rebate Rule.\nMedicare Part D benefit re-design.\nH.R. 2113 - Prescription Drug STAR Act.\nS. 551 - Recovering Excessive Funds for Unused and Needless Drugs (REFUND) Act.","USMCA","Prescription drug pricing.\nHHS Rebate Rule.\nMedicare Part D benefit re-design.\nH.R. 2113 - Prescription Drug STAR Act.\nS. 551 - Recovering Excessive Funds for Unused and Needless Drugs (REFUND) Act.\nH.R.3 - Lower Drug Costs Now Act of 2019\nS. 2543 - Prescription Drug Pricing Reduction Act of 2019","Prescription drug pricing.\nS. 1895 - Lower Health Care Costs Act\nS. 1416 - Affordable Prescriptions for Patients Act\nS. 1224 and H.R. 2374 - Stop Significant and Time-Wasting Abuse Limiting Legitimate Innovation of New Generics (STALLING) Act\nS. 440 - Preserving Access to Cost Effective Drugs Act\nS. 340 and H.R. 965 - CREATES Act\nS. 1391 & H.R. 2296 - Fair Accountability and Innovative Research Drug Pricing Act\nH.R. 1520 - Purple Book Continuity Act\nH.R. 1503 - Orange Book Continuity Act\nS. 659 - Biologic Patent Transparency Act\nS. 551 - Recovering Excessive Funds for Unused and Needless Drugs (REFUND) Act\nS. 1209 - Reforming Evergreening and Manipulation that Extends Drug Years (REMEDY) Act\nH.R. 2113 - Prescription Drug STAR Act\nS. 617 - Second Look at Drug Patents Act of 2019\nH.R.3 - Lower Drug Costs Now Act of 2019\nS. 2543 - Prescription Drug Pricing Reduction Act of 2019","Prescription drug pricing.\nS. 1895 - Lower Health Care Costs Act\nS. 1416 - Affordable Prescriptions for Patients Act\nS. 1224 and H.R. 2374 - Stop Significant and Time-Wasting Abuse Limiting Legitimate Innovation of New Generics (STALLING) Act\nS. 440 - Preserving Access to Cost Effective Drugs Act\nS. 340 and H.R. 965 - CREATES Act\nS. 1391 & S. 2296 - Fair Accountability and Innovative Research Drug Pricing Act\nH.R. 1520 - Purple Book Continuity Act\nH.R. 1503 - Orange Book Continuity Act\nS. 659 - Biologic Patent Transparency Act\nS. 551 - Recovering Excessive Funds for Unused and Needless Drugs (REFUND) Act\nS. 1209 - Reforming Evergreening and Manipulation that Extends Drug Years (REMEDY) Act\nH.R. 2113 - Prescription Drug STAR Act\nH.R. 985 - FAST Generics Act of 2019\nH.R.3 - Lower Drug Costs Now Act of 2019\nS. 2543 - Prescription Drug Pricing Reduction Act of 2019"],"years":[2018,2019,2020,2021,2022,2024,2025]}